Global In Vivo and In Vitro ADME Market Growth (Status and Outlook) 2025-2031

According to this study, the global In Vivo and In Vitro ADME market size will reach US$ million by 2031.

In the early stages of drug discovery, it is important to understand the key physicochemical properties and structural motifs that drive the efficacy and safety profile of a compound candidate. In vitro and in vivo ADME is used to identify the attributes of absorption, distribution, metabolism, and excretion. ADME assays are critical in gaining insight into metabolism and potential drug interactions.

United States market for In Vivo and In Vitro ADME is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for In Vivo and In Vitro ADME is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for In Vivo and In Vitro ADME is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key In Vivo and In Vitro ADME players cover Charles River, Labcorp, ICON, Syneos Health, Envigo, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “In Vivo and In Vitro ADME Industry Forecast” looks at past sales and reviews total world In Vivo and In Vitro ADME sales in 2024, providing a comprehensive analysis by region and market sector of projected In Vivo and In Vitro ADME sales for 2025 through 2031. With In Vivo and In Vitro ADME sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world In Vivo and In Vitro ADME industry.

This Insight Report provides a comprehensive analysis of the global In Vivo and In Vitro ADME landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on In Vivo and In Vitro ADME portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global In Vivo and In Vitro ADME market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for In Vivo and In Vitro ADME and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global In Vivo and In Vitro ADME.

This report presents a comprehensive overview, market shares, and growth opportunities of In Vivo and In Vitro ADME market by product type, application, key players and key regions and countries.

Segmentation by Type:
Small Molecules
Biologics

Segmentation by Application:
Biopharmaceutical Companies
Government and Academic Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Charles River
Labcorp
ICON
Syneos Health
Envigo
Curia
Evotec
Bioduro-Sundia
Lonza
WuXi AppTec
IQVIA
Tecan Group
Pharmaron
Shanghai Medicilon
ChemPartner
Joinn Laboratories
RTI International
Eurofins Scientific
Aragen Life Sciences
Sai Life Sciences

Please note: The report will take approximately 2 business days to prepare and deliver. Show more